Investor Home

Investor Home

Webcast ImageWebcast
Nabriva Therapeutics at Leerink Conference (Replay)
02/15/17 at 12:00 p.m. ET
Nabriva Therapeutics at Leerink Conference
Wednesday, February 15, 2017  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Nabriva Therapeutics RBC 2017 Healthcare Conference  (Live)
02/22/17 at 11:00 a.m. ET
Nabriva Therapeutics RBC 2017 Healthcare Conference
Wednesday, February 22, 2017 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>

Recent Newsmore >
02/08/17
Nabriva Therapeutics to Participate in Two Investor Conferences in February
VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., Chief Executive Officer of Nabriva Therapeutics, will provide a company overview and business update at the following conferences in February. ... 
02/02/17
Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
LEAP 1 top-line efficacy and safety data expected in 3Q17 VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that following a blinded interim analysis, an independent committee recommended no sample size adjustment fo... 
12/20/16
Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
-Blinded interim analysis to confirm sample size expected in February 2017 VIENNA, Austria and KING OF PRUSSIA, Pa., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has achieved 60% of its enrollment target in the lefamulin evaluation against pneumo... 
Upcoming Eventsmore >
DateTitleRemind
Me
Prior to
Event
02/22/17 11:00 a.m. ET
Nabriva Therapeutics RBC 2017 Healthcare Conference
  
Data provided by Nasdaq. Minimum 15 minutes delayed.